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Abstract
Background: Antiretroviral therapy is recommended during pregnancy to decrease the risk of perinatal transmission
of HIV-1 infection and to improve maternal health. However, some studies have reported that antiretroviral treatment
(ART) containing protease inhibitors (PI) is associated with an increased risk of preterm birth. In contrast, other studies
have reported no increased risk. This meta-analysis was conducted to derive a more reliable estimate of the association
between the prenatal use of PI based ART regimen and preterm birth.
Methods: A systemic review and meta-analysis was conducted using published studies which were identified
through a computerized search using the Medline/PubMed database, Google Scholar and Health Inter Network Access
to Research Initiative (HINARI). The analysis was undertaken using STATA version 11.0 software and studies
were described by forest plot. Heterogeneity across studies was checked using Cochran Q test and I2 test.
An adjusted odd ratio with 95 % confidence intervals [95 % CI] was pooled using a random effects model.
Results: The Cochrane Q test (Q test p = 0.051) showed a good homogeneity among studies. However,
medium heterogeneity was observed in up to 46 % of the sample using the I2 test (I2 = 46.5 %). The Egger
weighted regression method (p = 0.04) showed evidence of publication bias, but Begg rank correlation
statistics (p = 0.47) did not show evidence of publication bias. The pooled analysis of 10 studies showed that
protease based ART exposure during pregnancy was associated with an increased risk of preterm birth
(pooled odds ratio 1.32 (95 % CI, 1.04 to 1.59).
Conclusions: This meta-analysis revealed that the PI based ART exposure during pregnancy is significantly
associated with an increased risk of preterm birth. There should be strong cautions against initiating ART
during pregnancy and PI based ARV should be replaced by others drug regime. Protease inhibitor ART drugs
should not be included as part of therapy during pregnancy.
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Background
The introduction of antiretroviral agents has been suc-
cessful in reducing of human immune virus (HIV) trans-
mission from mother to baby [1–5]. Antiretroviral therapy
(ART) is recommended during pregnancy to decrease the
risk of perinatal transmission of HIV-1 infection and to
improve maternal health [6]. Pregnant women with symp-
tomatic HIV [7], high viral loads, and low CD4+ cell
counts are more likely to be treated with highly active
antiretroviral therapy (HAART), including ART with pro-
tease inhibitors (PIs) [8]. The World Health Organization
(WHO) now recommends HAART as an option of
mother to child transmission (PMTCT) during pregnancy
for all HIV-infected women with CD4 cell counts less than
350 cells/mm3 [1].
Safety concerns have been raised about the use of PI
antiretroviral agents [9]. A systemic review revealed that
low birth weight (LBW) and preterm birth (PTB) were
observed in women receiving PI based ART. Treatment
regimens including protease inhibitor and timing of
ART initiation (at early pregnancy) are factors associated
with these adverse pregnancy outcomes [10].
These uncertainties, especially the association be-
tween PI-based ART regimens and preterm births,
remain unresolved. Other studies exploring the asso-
ciation between ART including PIs and preterm birth
[7–9, 11–19] had shown conflicting results. Some of
these observational studies found an increased risk of pre-
term birth [7, 8, 11, 12, 15–20] while other studies have
reported no increased risk of preterm birth [9, 13, 14].
It is crucial to evaluate the effect of PI-based ART
exposure during pregnancy and the risk of prematurity/
preterm births to solve these controversies. Therefore,
we conducted a meta-analysis of all the relevant studies
published to date in order to provide a more reliable
overall estimate of the association between prenatal uses
of PI-based ART regimens and prematurity. This paper
summarizes the evidence of the association between PI-
based ART regimens and preterm births through a
systemic review and meta-analysis of studies.
Methods
Study design and data source
We assessed and analyzed available evidence on the
following question: does the use of any PI based anti-
retroviral drugs by HIV infected women that was started
at any appoint during pregnancy or preconception lead
to an increased risk of prematurity? We defined prematur-
ity as a newborn of less than 37 completed weeks of gesta-
tion, in HIV-infected women. A systematic review and
meta-analysis of studies that reported the association be-
tween PI based ART and PTB was conducted. We identi-
fied English language publications in the Medline data
base, Google Scholar and HINARI (Health Inter Network
Access to Research Initiative). We also cross-checked the
reference lists with combinations of the key wards “risk
factors”, “antiretroviral therapy”, “HIV”, “pregnancy”, “pre-
maturity”, “protease inhibitors”, “preterm delivery” and
“low birth weight”. These mesh terms were used as a
combination of free text and thesaurus terms in different
variations. The review and data abstraction was performed
from November 1, 2014 to February, 2015.
Study selection
A systemic review and meta-analysis was conducted on
studies that reported the association between PI based
ART and preterm birth. Studies were selected for the
meta-analysis if they included an appropriate control
group for comparison (defined as a group of HIV-
infected women receiving antiretroviral agents without
PI during pregnancy), so that the effect of antiretroviral
agents on preterm delivery could be compared with a
group of HIV-infected women receiving PI based ART
therapy. We included studies where the women initiated
ART before and during pregnancy (in the first, second
or third trimester). The studies also presented adjusted
effect estimates in odds ratios, rate ratios, risk ratios and
hazard risk ratios.
Reports of original studies, unpublished master’s thesis
and PhD dissertations, which were written in English
also considered.
Commentary, editorials and reviews were excluded. In
addition, studies were excluded from the analysis for any
of the following reasons: articles that did not focus on PI
based ART, those that did not consider PI based ART as
risk factors (independent variable), and studies that did
not give effect estimates as odds ratios, rate ratios, or
risk ratios, or did not allow the computation of such
measures. Duplicate publication of the same study, arti-
cles available only in abstract form, articles with greater
than 20 % lost during follow up or non-response were
also excluded. The selection of articles for review was
done in three stages: titles alone, abstracts, and then full
text articles.
Methodological quality assessment
The following points were noted as the study quality
indicators: the use of right statistical measurement to
assess the association between preterm birth and PI
based ART exposure during pregnancy; assessment and
adjustment of potential confounders (demographic,
socio-economic and baseline characteristics of the study
population). Reporting of response rates, lost to follow
up and appraisal of internal validity of the study were
also considered as quality indicators.
All assessments were entered into pre-tested and stan-
dardized data extraction form. Studies were assessed for
quality in which studies with medium (fulfilling 50 % of
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the quality assessment parameter) and high quality were
included for analysis. The studies that reported out-
comes on at least 50 patients, the studies whose re-
sponse rate was greater than 80 %; those that reported
basic demographic data, and adjustment for covariates
like demographic, socio-economic and baseline charac-
teristics of the study population were considered as high
quality studies.
Data abstraction
The data abstraction was conducted independently by
two investigators (KT, AT) and cross checked by the
third researcher (YM). The selected studies were
reviewed using a pretested and standardized abstraction
format and the following data were extracted, title, au-
thors name, year published, country, study design, study
site/country of origin, sample size, response rate, other
factors adjusted for in the analysis, intervention (type of
antiretroviral therapy used, time of initiation during
pregnancy or before pregnancy), premature delivery def-
inition and rate, and measure of rate with its confidence
interval (CI). In order to standardize the results, all mea-
sures of effect were expressed as OR, and a 95 % CI was
calculated if this had not calculated. When there was a
discrepancy in data abstraction among the investigators,
it was resolved through discussion and consensus.
Statistical analysis
Epi data version 3.1 and STATA version 11 software
were used for data entry and analysis respectively. The
descriptions of original studies were made by tables and
forest plots. The pooled effect size of PI based ART ex-
posure on preterm birth was carried out using the Der
Simonian-Laird random-effects meta-analysis (random
effects model) and measured by odds ratio with a 95 %
confidence intervals [95 % CI].
Statistical heterogeneity and exploration of publication bias
Statistical heterogeneity was evaluated by Cochran’s Q
test. This shows the amount of between study hetero-
geneity and I2 statistic. The I2 statistic is a measure of
the percentage of variability (inconsistency) between
studies that is due to chance. The presence of statistical
heterogeneity was tested using Cochran’s Q test (p < 0.10
is considered statistically significant) and I2 test (values
of 25 %, 50 % and 75 % are considered to represent low,
medium and high heterogeneity respectively) [21].
The individual study odds ratio (OR) with 95 % confi-
dence intervals (CIs) were displayed using Funnel plots
to assess publication bias. The Egger weighted regression
and Begg rank correlation tests were used to assess pub-
lication bias (p < 0.05 is considered statistically signifi-
cant). Cumulative meta-analysis was also used to explore
the effect of each study and less precise studies on the
pooled estimates.
Ethical issues
Since this research is a systemic review and meta-




A total of 322 articles were identified through the litera-
ture search. Two additional articles were also obtained
manually. Of these, 290 were excluded after screening by
titles and abstracts. These were duplicated studies, case
reports, systematic reviews and meta-analyses. From the
remaining 44 articles, 32 were excluded because of one
or more of the following reasons, they were studies of
PMTCT, they did not consider PI based ART as an inde-
pendent/exposure variable, the full article or data could
not be accessed, they were on children, they were dealt
only with monotherapy, or they did not give a quantita-
tive effect estimate. Further studies were excluded that
did not adjust for covariates. Finally 10 articles were
used for the meta-analysis. See Fig. 1 for the flow dia-
gram for study selection.
Study characteristics
Eight of the 10 studies selected for the meta-analysis
were prospective cohort studies [8, 11–15, 17, 22], one
study was a randomized trial study [23] and there was
one surveillance study [16]. These 10 selected studies
addressed the association between PI based ART and
preterm birth, and had sample size ranging from n = 183
in Germany and Austria [15] to n = 5009 in UK [16].
The studies were carried out between 2002 [22] and
2013 [13]. All studies were reported in English. These
studies represented 19 countries across 5 continents
(Africa, Europe, Latin America, and North America).
General characteristics and a description of the studies
selected are available in Table 1.
Assessing heterogeneity and publication bias among the
studies
The studies showed heterogeneity using Cochrane Q
test statistic (Q test p = 0.051). Medium heterogeneity
was observed up to 46 % using the I2 test (I2 = 46.5 %)
which was indicative of using random-effects model.
The asymmetrical distribution of effects estimate using
traditional funnel plot (Fig. 2), Begg’s funnel plots (Fig. 3)
and the Egger weighted regression method (p = 0.04)
showed evidence of publication bias. However, Begg rank
correlation statistics (p = 0.47) showed no evidence of
publication bias.
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The Association of PI based ART during pregnancy and
preterm birth
Based on the ten studies that reported premature deliv-
ery in association to the use of PI based ART regimens
during pregnancy, the pooled odd ratio according to
random effect model was 1.32 (95 % CI 1.04 to 1.59).
This meta-analysis revealed that the PI based ART is
associated with an increased risk of premature births
(Fig. 4).
Based on the sub group analysis, we found moderate
heterogeneity of effects estimate from studies that initi-
ated ART during 3rd trimesters between study variance
322 Titles identified from Medline/Pubmed, 
Google Scholar and HINARI data base 
literature search
42 Articles retained for full text review
44 Articles retained for full text review
280 Articles excluded based on 
titles and abstracts
10 Articles included in Meta-analysis   
32 Articles do not meet the 
inclusion criteria and were 
excluded after quality analysis
No comparison group 
No ART Group 
Indirectness of the finding 
Confounders are not controlled
2 Articles were added from 
manual search 
Fig. 1 Flow chart diagram describing selection of studies for a systematic review (identification, screening, eligible and included studies). Articles
may have been excluded for more than one reason
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accounted for 58 % and 60 % before pregnancy & be-
tween the 1st and 3rd trimesters. The low heterogeneity
of effect estimate (I2 = 0 %) of the total variance among
studies which initiated ART between 1st and 3rd trimes-
ters was noted. The pooled effects estimate for studies
that initiated ART between the 1st and 3rd trimesters
(4 studies) was 1.51 (95 % CI 1.07, 1.9). The pooled effects
estimate for studies that initiated ART during 3rd
trimester (2 studies) was 1.46 (95 % CI 0.73, 2.1). Likewise,
the pooled effects estimate for studies that initiated ART
before pregnancy & between the 1st and 3rd trimesters
(4 studies) was 1.59 (95 % CI 0.49, 2.6) (Fig. 5).
Discussion
The advent of ART has been successful in saving
many lives [1, 5]. In the era of zidovudine and
Table 1 Summary of the 10 observational studies assessing the association between Protease Inhibitors based ART and preterm









AOR (95 % CI)
Cotter AM et al.,
2006 [8]
Prospective 999 Miami, Florida, USA Combination without PI <12wk,12–23wk, 3rd
trimester
<37wk 1.8 (1.1,3.0)
Powis KM, et al.,
2011 [23]






et al., 2007 [11]
Prospective 183 Germany & Austria Mono therapy >2wks before conception)
or during pregnancy
<36wk 3.40 (1.13–10.2)
Schulte J, et al.,
2012 [12]
Prospe 8793 Atalanta, Georgia 2drugs 26–42wk 37 1.21 (1.04–1.40)
Watts DH et al.,
2013 [24]
Cohort 1869 USA Mono or dual therapy 1st -3rd trimester 37 1.49 (0.83,2.66)
Tuomala RE et al.,
2002 [13]
Trial & cohort 2123 Boston USA Combination without PI 1st -3rd trimeste 37 1.80 (0.94–3.43)
Patel K et al.,
2011 [22]
Prospe cohort 777 USA Mono/combination
without PI
1st -3rd trimeste 37 1.29 (0.77, 2.15)






1–2 NRTI Before/during pregnancy 37 1.1 (0.5–2.8)
Townsend CL
et al., 2007 [15]
Surveillance 5009 UK Combination Before/during pregnancy 37 0.96 (0.78,1.19)
Hankin C et al.,
2003 [16]
















-2 -1 1 2 3 4
var12adjus
Funnel plot with pseudo 95% confidence limits
Fig. 2 Funnel plot of with 95 % confidence limit; the horizontal line in the funnel plot indicates the effect estimate, while the sloping lines
indicate the expected 95 % confidence intervals
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combination therapy, in utero transmission of HIV
has been drastically reduced. It is evident that many
children are born HIV free due to ART [2, 3]. Des-
pite the fact that ART prevents HIV transmission
from mother to fetus, several studies have reported
that ART was associated with a risk of premature
birth. Some studies linked the PI based ART with
PTB [4, 8, 11, 12, 15, 16, 23], whereas other studies
have reported PI-based ART presents no risk for
PTB [13, 14, 22, 24].















Fig. 3 Begg’s funnel plot with 95 % confidence limit; the horizontal line in the funnel plot indicates the natural logarithms of the effect estimate,
while the sloping lines indicate the expected 95 % confidence intervals
NOTE: Weights are from random effects analysis
Overall  (I-squared = 46.5%, p = 0.051)
Szylda EG et al, 2006
Tuomala  RET et al, 2002
Watts DH et al, 2013
Schulte J et al,2012




Powis KM et al, 2011
Townsend CL et al 2007
Hankin C et al 2003


























1 10.20.5 2 3 4
Fig. 4 Forest plot of the 10 observational studies that quantitatively assessed the association between PI based ART and preterm birth. Size of the
square is proportional to the precision of the study-specific effect estimates, and the bars indicate the corresponding 95 % CIs. The diamond is
centered on the summary OR of the studies, and the width indicates the corresponding 95 % CI
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This meta-analysis used 10 studies that reported the
association between PI based ART and PTB in order to
explore this disparity. Six of the identified studies re-
ported that PI based ART was significantly associated
with a higher risk of preterm birth [8, 11, 12, 15, 16, 23].
However, four studies revealed no significant in-
creased risk of preterm birth linked with PI based
ART [13, 14, 22, 24]. This meta-analysis combined these
studies found that the PI based ART is significantly associ-
ated with an increased risk of preterm birth. According to
the results of this meta-analysis, the risk of experiencing
PTB by those who received PI based ART regimens was
higher by 32 %. This result is consistent with a meta-
analysis conducted in 2007 [9] even though its result was
pooled by using unadjusted OR. Likewise, a European col-
laborative study across 9 European countries showed a
higher risk of preterm birth among women who had re-
ceived PI based ART compared with no ART [16]. This
might be linked to the fact that a combination therapy
with PI had been prescribed for the advanced and com-
plex conditions, thus mothers might have been in compli-
cated status and then their fetus would be affected.
This increased risk could be confounded by different
factors other than the treatment under consideration.
However, the included articles tried to adjust for several
variables. The European Collaborative Study adjusted for
maternal CD4 T-cell count, race, age and illicit drug use;
the US studies by Tuomala et al. [17] and Cotter et al
[21] also adjusted for previous premature delivery and
the use of alcohol and tobacco. The study by Cotter
et al. [21] also adjusted for the year of delivery and the
duration of antiretroviral therapy during pregnancy.
However, other unconsidered variables might have an ef-
fect on PTB. Therefore, this result should interpreted
cautiously. However, this result has shown the implica-
tion of PI based ART on the normal growth of fetus. On
the other hand, these PI drugs are taken as a second
options for prescription and precaution have to be taken
to be used by the pregnant mothers. Physicians in charge
of the care of HIV positive pregnant women should
substitute PI regimens by using alternative drugs.
This meta-analysis, unlike previous reviews [9], in-
cludes 10 recent studies which had adjusted OR that
examined the association of PI based ART and preterm
birth as well as generating the overall pooled summary
estimates regarding the overall association between PI-
based ART and PTB. Additionally this meta-analysis
documented no significant heterogeneity among the
studies, but this was not stated in the previous meta-
analysis.
Limitations
In general, the result of systematic reviews and meta-
analysis needs to be interpreted in the context of the
study methodologies. It is possible that confounders
other than ART exposure may be responsible for the ob-
served differences in the reported outcomes. However,
we mostly selected studies that stated and accounted for




Overall  (I-squared = 46.5%, p = 0.051)
Subtotal  (I-squared = 60.7%, p = 0.054)
Watts DH et al, 2013
Cotter AM et al,2006
Hankin C et al 2003
Before pregnancy & 1st-3rd trimester
Subtotal  (I-squared = 58.2%, p = 0.122)
Szylda EG et al, 2006
TUomala  RET et al, 2002
Schulte J et al,2012
Powis KM et al, 2011
1st-3rd trimester
Townsend CL et al 2007
Patel K  et al,2011
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Fig. 5 Forest plot of the 10 observational studies that quantitatively assessed the association between PI based ART and preterm birth by time of
ART initiation during pregnancy
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possible confounders. Another likely source of bias in
this review may be publication bias. Studies which find
no, or negative associations, may be less likely to be pub-
lished either because they are not submitted for publica-
tion, or because journals are less likely to publish them.
There are several potential limitations to this study.
The analysis was based on estimates derived from obser-
vational studies that are vulnerable to confounding vari-
ables. To address the issue of potential confounders, a
sensitivity analysis was performed; separate summary es-
timates were reported for the studies that adjusted for
important potential confounders and those that did not.
Conclusion
This meta-analysis revealed that PI based ART exposure
during pregnancy is significantly associated with an in-
creased risk of preterm birth. There should be strong
cautions in initiating PI based ART during pregnancy
and should be replaced by others. We conclude that the
proteinase inhibitor ART drugs should not be included
as part of first-line therapy during pregnancy.
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